Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 3/20 | 0.69 |
| ▸ | JAK1 | P23458 | 4/20 | 0.63 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.63 |
| ▸ | JAK3 | P52333 | 1/20 | 0.58 |
| ▸ | FYN | P06241 | 8/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3262251 | 0.89 | NUDT1 (0.71) | NUDT1JAK1EGLN2JAK3JAK2 | |
| SCHEMBL2730823 | 0.87 | NUDT1 (0.68) | NUDT1JAK1EGLN2JAK3JAK2 | |
| SCHEMBL3601961 | 0.84 | NUDT1 (0.78) | NUDT1JAK1EGLN2JAK3JAK2 | |
| SCHEMBL3200526 | 0.83 | NUDT1 (0.76) | NUDT1JAK1EGLN2JAK3JAK2 | |
| SCHEMBL2144054 | 0.82 | NUDT1 (1.00) | NUDT1JAK1EGLN2JAK3JAK2 | |
| SCHEMBL2250300 | 0.81 | NUDT1 (0.73) | NUDT1JAK1EGLN2JAK3JAK2 | |
| SCHEMBL22499606 | 0.81 | NUDT1 (0.73) | NUDT1JAK1EGLN2JAK3JAK2 | |
| SCHEMBL2363033 | 0.81 | NUDT1 (0.73) | NUDT1JAK1EGLN2JAK3JAK2 | |
| SCHEMBL15654035 | 0.81 | JAK1 (0.77) | NUDT1JAK1EGLN2JAK3JAK2 | |
| Bromide SCHEMBL28482737 | 0.81 | NUDT1 (0.44) | NUDT1JAK1EGLN2JAK3FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12042498-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | ALFASIGMA S.P.A. (IT) | 2024-07-23 | — | — | US | disclosed |
| US-20230406857-A1 | SALTS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ALFASIGMA S.P.A. (IT) | 2023-12-21 | — | — | US | disclosed |
| EP-3283114-B1 | METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | GALAPAGOS NV (BE) | 2023-09-06 | — | — | EP | disclosed |
| US-11667633-B2 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2023-06-06 | — | — | US | disclosed |
| US-20210369727-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2021-12-02 | — | — | US | disclosed |
| EP-3842432-A1 | NOVEL SALTS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos N.V. (BE) | 2021-06-30 | — | — | EP | disclosed |
| US-11000528-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2021-05-11 | — | — | US | disclosed |
| US-10919890-B2 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2021-02-16 | — | — | US | disclosed |
| EP-3102575-B1 | NOVEL SALTS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2021-01-13 | — | — | EP | disclosed |
| US-20200244651-A1 | NOVEL SALTS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ALFASIGMA S.P.A. (IT) | 2020-07-30 | — | — | US | disclosed |
| US-8999979-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2015-04-07 | — | — | US | disclosed |
| US-8853240-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2014-10-07 | — | — | US | disclosed |
| EP-2361251-B1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-04-30 | — | — | EP | disclosed |
| US-20140100220-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV | 2014-04-10 | — | — | US | disclosed |
| US-8563545-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2013-10-22 | — | — | US | disclosed |
| US-20120142678-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV | 2012-06-07 | — | — | US | disclosed |
| EP-2445911-A1 | 5-PHENYL-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-YL CARBOXAMIDES AS JAK INHIBITORS | Galapagos N.V. (BE) | 2012-05-02 | — | — | EP | disclosed |
| US-20100331319-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2010-12-30 | — | — | US | disclosed |
| WO-2010149769-A1 | 5-PHENYL-[1,2,4 ]TRIAZOLO[1,5-A]PYRIDIN-2-YL CARBOXAMIDES AS JAK INHIBITORS | GALAPAGOS NV (BE) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010010190-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331319-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, JAK1, BMP6 | NUDT1 3558/4885JAK1 2/4885EGLN2 2017/4885 |
| US-10919890-B2 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | IL6, JAK1, COL1A1 | NUDT1 1732/4885JAK1 2/4885EGLN2 3165/4885 |
| US-11667633-B2 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | IL6, JAK1, COL1A1 | NUDT1 1732/4885JAK1 2/4885EGLN2 3165/4885 |
| US-20140100220-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, JAK1, BMP6 | NUDT1 3558/4885JAK1 2/4885EGLN2 2017/4885 |
| US-20120142678-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, JAK1, BMP6 | NUDT1 3558/4885JAK1 2/4885EGLN2 2017/4885 |
| US-12042498-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | IL6, JAK1, BMP6 | NUDT1 3774/4885JAK1 2/4885EGLN2 1539/4885 |
| US-20210369727-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, JAK1, BMP6 | NUDT1 3558/4885JAK1 2/4885EGLN2 2017/4885 |
| US-11000528-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | IL6, JAK1, BMP6 | NUDT1 3774/4885JAK1 2/4885EGLN2 1539/4885 |
| US-20230406857-A1 | SALTS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | IL6, JAK1, COL1A1 | NUDT1 1732/4885JAK1 2/4885EGLN2 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.